[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

FI103380B1 - A composition and method for stabilizing blood plasma during pasteurization - Google Patents

A composition and method for stabilizing blood plasma during pasteurization

Info

Publication number
FI103380B1
FI103380B1 FI930630A FI930630A FI103380B1 FI 103380 B1 FI103380 B1 FI 103380B1 FI 930630 A FI930630 A FI 930630A FI 930630 A FI930630 A FI 930630A FI 103380 B1 FI103380 B1 FI 103380B1
Authority
FI
Finland
Prior art keywords
composition
blood plasma
plasma during
plasma
stabilizing blood
Prior art date
Application number
FI930630A
Other languages
Finnish (fi)
Swedish (sv)
Other versions
FI930630A0 (en
FI103380B (en
FI930630A (en
Inventor
Miryana Nee Radosevich Burnouf
Original Assignee
Aetsrn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aetsrn filed Critical Aetsrn
Publication of FI930630A0 publication Critical patent/FI930630A0/en
Publication of FI930630A publication Critical patent/FI930630A/en
Application granted granted Critical
Publication of FI103380B1 publication Critical patent/FI103380B1/en
Publication of FI103380B publication Critical patent/FI103380B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
    • A61L2/0023—Heat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • External Artificial Organs (AREA)

Abstract

The invention relates to a composition intended to stabilise blood plasma during pasteurisation, the blood plasma being whole or devoid of cryoproteins. The composition according to the invention makes it possible to pasteurise very large quantities of plasma (of the order of 60 litres). The invention also relates to the method for pasteurisation of the plasma using the stabilising composition. The pasteurised plasma obtained is intended for therapeutic use.
FI930630A 1992-02-13 1993-02-12 A composition and method for stabilizing blood plasma during pasteurization FI103380B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9201604A FR2687317B1 (en) 1992-02-13 1992-02-13 COMPOSITION FOR STABILIZING BLOOD PLASMA DURING PASTEURIZATION AND PASTEURIZED PLASMATIC SOLUTION FOR THERAPEUTIC USE.

Publications (4)

Publication Number Publication Date
FI930630A0 FI930630A0 (en) 1993-02-12
FI930630A FI930630A (en) 1993-08-14
FI103380B1 true FI103380B1 (en) 1999-06-30
FI103380B FI103380B (en) 1999-06-30

Family

ID=9426597

Family Applications (1)

Application Number Title Priority Date Filing Date
FI930630A FI103380B (en) 1992-02-13 1993-02-12 A composition and method for stabilizing blood plasma during pasteurization

Country Status (20)

Country Link
EP (1) EP0556096B1 (en)
JP (2) JP4010573B2 (en)
AT (1) ATE171074T1 (en)
BR (1) BR9300524A (en)
CA (1) CA2089446C (en)
CZ (1) CZ285573B6 (en)
DE (1) DE69321007T2 (en)
DK (1) DK0556096T3 (en)
EE (1) EE03091B1 (en)
ES (1) ES2121065T3 (en)
FI (1) FI103380B (en)
FR (1) FR2687317B1 (en)
HU (1) HU210026B (en)
LT (1) LT3226B (en)
LV (1) LV10195B (en)
NO (1) NO306532B1 (en)
PL (1) PL174098B1 (en)
RU (1) RU2112522C1 (en)
SK (1) SK280665B6 (en)
UA (1) UA27102C2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9501189D0 (en) * 1995-03-31 1995-03-31 Pharmacia Ab Protein formulation
US5616159A (en) * 1995-04-14 1997-04-01 Corning Incorporated Method of forming high purity fused silica having high resistance to optical damage
US6619073B2 (en) 1996-03-05 2003-09-16 Corning Incorporated Method of increasing the initial transmittance of optical glass
US5962213A (en) * 1996-06-14 1999-10-05 Biostore New Zealand Limited Compositions and methods for the preservation of living tissues
US5879875A (en) * 1996-06-14 1999-03-09 Biostore New Zealand Compositions and methods for the preservation of living tissues
WO1997047192A1 (en) * 1996-06-14 1997-12-18 Biostore New Zealand Limited Compositions and methods for the preservation of living tissues
US6361933B1 (en) 1996-06-14 2002-03-26 Biostore New Zealand Limited Solutions for the preservation of tissues
US6114107A (en) * 1996-06-14 2000-09-05 Biostore New Zealand Limited Composition comprising raffinose, TMAO, sodium citrate and methods for the preservation of living tissues
US6037116A (en) * 1996-06-14 2000-03-14 Biostore New Zealand, Ltd. Compositions comprising betaine, sodium citrate and sodium chloride and methods for the preservation of biological materials
US5827640A (en) * 1996-06-14 1998-10-27 Biostore New Zealand Limited Methods for the preservation of cells and tissues using trimethylamine oxide or betaine with raffinose or trehalose
US6915665B2 (en) 2000-10-31 2005-07-12 Corning Incorporated Method of inducing transmission in optical lithography preforms
US20060019234A1 (en) * 2004-07-22 2006-01-26 Shanbrom Technologies, Llc Modern blood banking employing improved cell preservation composition
ES2264403B1 (en) * 2006-06-22 2007-11-01 Grifols S.A. HEMATIES SUSPENSION MEDIA.
DE102011056142A1 (en) * 2011-12-07 2013-06-13 Manfred Rüdinger Metabolizable salts and their use in diagnostics and therapy
RU2639446C1 (en) * 2016-11-23 2017-12-21 Федеральное государственное бюджетное образовательное учреждение высшего образования "Ярославский государственный медицинский университет" Министерства здравоохранения Российской Федерации Method for storage of blood plasma containing drugs with unstable phenolic hydroxiles

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3045153A1 (en) * 1980-11-29 1982-07-08 Behringwerke Ag, 3550 Marburg METHOD FOR THE PRODUCTION OF BLOOD COagulation FACTORS AND THE PREPARATION OF FACTORS IX AND X THEREFORE PRODUCED
DE3230849A1 (en) * 1982-08-19 1984-02-23 Behringwerke Ag, 3550 Marburg PASTEURIZED HUMAN FIBRINOGEN (HF) AND METHOD FOR THE PRODUCTION THEREOF
DE3237512A1 (en) * 1982-10-09 1984-04-12 Behringwerke Ag, 3550 Marburg METHOD FOR PASTEURIZING ANTIHAEMOPHILIC CRYOPRAEZIPITATE (AHK) AND ANTIHAEMOPHILE CRYOPRAECIPITATE PRODUCED THEREOF
US4470968A (en) * 1983-01-13 1984-09-11 Miles Laboratories, Inc. Pasteurized therapeutically active blood coagulation factor concentrates
JPS59134730A (en) * 1983-01-20 1984-08-02 Green Cross Corp:The Heat treatment of viii factor of blood clotting
DE3330770A1 (en) * 1983-08-26 1985-03-14 Behringwerke Ag, 3550 Marburg METHOD FOR PASTEURIZING HUMAN PLASMA
FR2650508A1 (en) * 1989-08-01 1991-02-08 Fondation Nale Transfusion San PASTEURIZED ADHESIVE FOR JOINING HUMAN OR ANIMAL TISSUES
FR2664165B1 (en) 1990-07-03 1992-10-16 Lille Transfusion Sanguine COMPOSITION FOR STABILIZING BLOOD PLASMA DURING PASTEURIZATION.

Also Published As

Publication number Publication date
LV10195A (en) 1994-10-20
FR2687317B1 (en) 1995-06-23
FR2687317A1 (en) 1993-08-20
FI930630A0 (en) 1993-02-12
CZ16193A3 (en) 1993-12-15
JPH0624997A (en) 1994-02-01
UA27102C2 (en) 2000-02-28
JP4472672B2 (en) 2010-06-02
DE69321007D1 (en) 1998-10-22
EP0556096A1 (en) 1993-08-18
FI103380B (en) 1999-06-30
DK0556096T3 (en) 1999-06-14
HU9300377D0 (en) 1993-04-28
ES2121065T3 (en) 1998-11-16
NO930473D0 (en) 1993-02-11
NO306532B1 (en) 1999-11-22
CA2089446C (en) 2006-04-18
CA2089446A1 (en) 1993-08-14
SK280665B6 (en) 2000-05-16
LT3226B (en) 1995-04-25
CZ285573B6 (en) 1999-09-15
BR9300524A (en) 1993-09-28
PL297699A1 (en) 1994-01-10
LTIP338A (en) 1994-08-25
EE03091B1 (en) 1998-06-15
ATE171074T1 (en) 1998-10-15
LV10195B (en) 1995-04-20
DE69321007T2 (en) 1999-04-01
HU210026B (en) 1995-01-30
HUT63768A (en) 1993-10-28
EP0556096B1 (en) 1998-09-16
PL174098B1 (en) 1998-06-30
FI930630A (en) 1993-08-14
JP2006306892A (en) 2006-11-09
NO930473L (en) 1993-08-16
RU2112522C1 (en) 1998-06-10
JP4010573B2 (en) 2007-11-21
SK8293A3 (en) 1993-10-06

Similar Documents

Publication Publication Date Title
FI103380B (en) A composition and method for stabilizing blood plasma during pasteurization
TW271405B (en)
EP0552240A4 (en) New method of treating depression
RU93004727A (en) COMPOSITION FOR STABILIZING BLOOD PLASMA, METHOD FOR PASTERIZING PLASMA AND USING STABILIZED PLASMA IN THERAPY
ATE222491T1 (en) MELATONIN DERIVATIVES FOR USE IN THE TREATMENT OF SLEEP DISORDERS
DE69432626D1 (en) Melatonin derivatives for use in the treatment of desynchronization disorders
FR2664165B1 (en) COMPOSITION FOR STABILIZING BLOOD PLASMA DURING PASTEURIZATION.
EP0353910A3 (en) Human interferon-gamma, process for preparing said human interferon-gamma, and its use
GB8630697D0 (en) Compositions of matter
DE59400836D1 (en) Liquid gas formulation for vitality testing of teeth
EP0376608A3 (en) Benzamide derivatives as antiarrhythmics
GEP19991579B (en) Method for Shunting of Arteries

Legal Events

Date Code Title Description
PC Transfer of assignment of patent

Owner name: L ÉTABLISSEMENT FRANçAIS DU SANG

Free format text: L ÉTABLISSEMENT FRANçAIS DU SANG

MM Patent lapsed